Peptide Half-Life

Q: Why do most peptides have short half-lives?

Peptides are rapidly degraded by circulating peptidases and proteases in blood, and small peptides are cleared by the kidneys. This is why most natural peptides act locally and briefly.

Q: How do modifications extend peptide half-life?

Fatty acid chains (acylation) allow the peptide to bind albumin, shielding it from proteases. PEGylation adds polyethylene glycol chains that increase size and reduce renal clearance. Both approaches extend circulating time.

Peptide Half-Life

Peptide Plasma Half-Life

Research Use Only · Not for Human Consumption

Half-life (t½) in pharmacokinetics refers to the time it takes for the concentration of a compound in the bloodstream to decrease by 50%. For research peptides, half-life is a critical parameter that determines dosing frequency in research protocols. Most unmodified peptides have very short half-lives (minutes to hours) due to rapid degradation by circulating proteases and renal clearance. Modifications such as PEGylation, fatty acid conjugation (acylation), and albumin binding are used to extend half-life.

Key Facts

Definition: Time for plasma concentration to fall 50%
Short-lived example: Native GLP-1: ~2 min
Extended example: Semaglutide: ~7 days
Extension methods: Acylation, PEGylation, albumin binding

Research Applications

Dosing interval determination in research protocols
Pharmacokinetic modeling
Comparing native vs modified peptide stability
Drug design optimization research

Frequently Asked Questions

Why do most peptides have short half-lives?

How do modifications extend peptide half-life?

Stock Peptide Half-Life on Your Research Compound Store

PeptiCommerce provides turn-key access to COA-documented research compounds. Your branded WooCommerce store with P2P and crypto payment support, ready in under 72 hours.

Get Started →

Key Facts

Research Applications

Frequently Asked Questions

Related Terms

Get the Research Peptide Business Playbook